Premium
Estrogen receptor protein in breast cancer as a predictor of recurrence
Author(s) -
Kinne David W.,
Ashikari Roy,
Butler Avital,
MenendezBotet Celia,
Rosen Paul Peter,
Schwartz Morton
Publication year - 1981
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19810515)47:10<2364::aid-cncr2820471007>3.0.co;2-s
Subject(s) - medicine , breast cancer , estrogen receptor , estrogen , adjuvant , oncology , oestrogen receptor , adjuvant chemotherapy , adjuvant therapy , chemotherapy , receptor , affect (linguistics) , cancer , progesterone receptor , linguistics , philosophy
Estrogen receptor protein (ERP) determinations of primary cancers of 1034 patients with primary breast cancer were done. ERP‐positive patients tended to have a lower recurrence rate and had significantly improved survival. This difference was most apparent in patients with four or more axillary nodes involved. ERP‐positive patients who recurred had a better survival. ERP did not influence response to adjuvant chemotherapy, nor did the presence of progesterone receptor or femtomole level of ERP affect recurrence.